Development and characterization of ligand-appended liposomes for multiple drug therapy for pulmonary tuberculosis
Source abstract
Abstract
Tuberculosis (TB) remains one of the oldest and deadliest diseases in the current scenario. The intracellular organism Mycobacterium tuberculosis, which mainly resides in mononuclear phagocytes, is responsible for tuberculosis in humans. A few therapies are available for the treatment of tuberculosis but they have many hurdles. To overcome these hurdles, a combination of chemotherapeutic agent-loaded vesicular systems have been prepared to overcome tuberculosis. To investigate the role of novel drug delivery systems for the treatment of pulmonary tuberculosis, ligand appended liposomals have been developed. In the present study, drug-loaded, ligand-appended liposomes and their DPI (Dry Powder Inhaler) forms have been prepared and characterized using various in vitro and in vivo parameters. The prepared ligand-appended liposomal formulation showed good entrapment efficiency, prolonged drug release, improved recovery of drugs from the target site, and proved to be more suitable for use as DPI, justifying their potential for improved drug delivery. Thus we tried our best by our project to reduce the national burden of tuberculosis, which is still a global health challenge.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Inhalation and Respiratory Drug Delivery · Pneumocystis jirovecii pneumonia detection and treatment · Pneumonia and Respiratory Infections
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (19)
Show source-provided references
1. Alcais A · J Exp Med. · 2005 · 202 · 161710.1084/jem.20052302 ↗
2. Brosch R · Proc Natl Acad Sci. · 2002 · 99 · 368410.1073/pnas.052548299 ↗
3. Churchyard GJ, Wallis R, Levin J, Kaplan G, Onyebujoh P, Vahedi M. 2007. Report of the expert consultation on immunotherapeutic interventions for tuberculosis. WHO. Geneva, 1–56.
4. Conte JE · Antimicrob Agents Chemother. · 2000 · 44 · 98510.1128/AAC.44.4.985-990.2000 ↗
5. 10.1016/S0092-8674(00)80754-010.1016/S0092-8674(00)80754-0 ↗
6. Gandhi NR · Lancet · 2006 · 368 · 157510.1016/S0140-6736(06)69573-1 ↗
7. Hopewell PC. · Tuberculosis: Pathogenesis, Protection, and Control · 1994 · 2510.1128/9781555818357.ch3 ↗
8. Jain KK · Methods. Mol Biol. · 2008 · 437 · 110.1007/978-1-59745-210-6_1 ↗
9. Kamholz SL. · 1996 · 483
10. Mansour HM · Int J Nanomed. · 2009 · 4 · 29910.2147/IJN.S4937 ↗
11. Mehta PK · Infect. Immun. · 1996 · 64 · 267310.1128/IAI.64.7.2673-2679.1996 ↗
12. Noss EH · J Immunol. · 2001 · 167 · 91010.4049/jimmunol.167.2.910 ↗
13. Pandey S · J Pharm Res. · 2009 · 2 · 1159
14. Papahadjopoulos D · Biochem Biophys Acta · 1973 · 330 · 910.1016/0005-2736(73)90280-0 ↗
15. Sally-Ann C · The AAPS Journal · 2005 · 7 · E2010.1208/aapsj070104 ↗
16. Smith I · Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clinical Microbiology Reviews · 2003 · 16 · 463
17. Via LE · J Biol Chem · 1997 · 272 · 1332610.1074/jbc.272.20.13326 ↗
18. 10.1517/17425247.4.2.9510.1517/17425247.4.2.95 ↗
19. Vyas SP · J Microencap. · 1994 · 11 · 37310.3109/02652049409034255 ↗